Table 1.

Characteristics of patients with autoimmune hepatitis after SARS-CoV-2 vaccine.

Study	Vaccine	Gender	Age	Autoimmune disease history	Antibodies	IgG	Biopsy	Steroid response
Bril et al	Pfizer-BioNTech	Female	35	None	ANA Anti-dsDNA	Normal	Compatible	Yes
Londono et al	Moderna	Female	41	None	ANA SMA SLA LC-1	High	Compatible	Yes
Clayton-Chubb et al.	Oxford-AstraZeneca	Male	36	None	ANA	Normal	Compatible	Yes
Tan et al.	Moderna	Female	56	None	ANA SMA	High	Compatible	Yes
McShane et al.	Moderna	Female	71	None	SMA	High	Compatible	Yes
Lodato et al.	Pfizer-BioNTech	Female	43	None	negative	Normal	Compatible	Yes
Rocco et al	Pfizer-BioNTech	Female	80	Hashimoto disease	ANA	High	Compatible	Yes
Rela et al (two cases)	Covishield	Female	38	None	ANA	High	Compatible	Yes
		Male	65	None	–	–	Compatible	Yes
Vuille-Lessard E et al Ghielmetti M et al	Moderna Moderna	Female Male	76 63	Hashimoto disease None	ANA ASMA anti-aktin ANCA ANA	High High	Compatible Compatible	Yes Yes

IgG, ımmunglobulin G; ANA, anti nuklear antikor; SMA, smooth muscle antibodies; dsDNA, double stranded DNA antibodies; LC1, liver sitozol antibody; anti-SLA, soluble liver antijen antibodies; ANCA, anti neutrophil cytoplasmic antibodies.